Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence

NCT ID: NCT02348112

Last Updated: 2023-12-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

416 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this postmarket study is to compare the safety and effectiveness of the Altis Single Incision Sling (SIS) to an FDA cleared transobturator and/or retropubic sling through 36 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, post-market, multi-center, cohort assessment comparing Altis SIS (n=178) and transobturator and/or retropubic slings (n=178) in the treatment of stress urinary incontinence at up to 40 U.S. and international sites. Subjects will be followed for a total of 36 months with scheduled visits at 6, 12, 18, 24 and 36 months. The study population will consist of adult female subjects with stress urinary incontinence who are clinically indicated for surgical intervention with a mesh sling.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stress urinary incontinence Altis 522 urinary incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Altis arm

Subjects will have an Altis sling placed to treat stress urinary incontinence.

Altis Single Incision Sling

Intervention Type DEVICE

Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.

Comparator arm

Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.

Transobturator or Retropubic Sling

Intervention Type DEVICE

Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Altis Single Incision Sling

Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.

Intervention Type DEVICE

Transobturator or Retropubic Sling

Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is female and at least 18 years of age.
* The subject is able and willing to complete all procedures and follow-up visits indicated in this protocol.
* The subject has confirmed stress urinary incontinence (SUI) through cough stress test or urodynamics.
* The subject has failed two non-invasive incontinence therapies (such as Kegel exercise, behavior modification, pad use, biofeedback, etc.) for \> 6 months.

Exclusion Criteria

* The subject has an active urogenital infection or active skin infection in region of surgery.
* The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as determined by POP-Q prolapse grading.
* The subject is having a concomitant pelvic floor procedure.
* The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions).
* The subject had a prior surgical stress urinary incontinence (SUI) treatment.
* The subject has undergone radiation or brachy therapy to treat pelvic cancer.
* The subject has urge predominant incontinence by MESA assessment.
* The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2 occasions.
* The subject is pregnant and/or is planning to get pregnant in the future.
* The subject has a contraindication to the surgical procedure or the product Instructions for Use (IFU).
* The subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function, without the sponsors approval.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coloplast A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ty Erickson, MD

Role: PRINCIPAL_INVESTIGATOR

Rosemark WomenCare Specialists

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University

Stanford, California, United States

Site Status

Pelvic Solutions Center

Denver, Colorado, United States

Site Status

Urology Specialists, LLC

Hialeah, Florida, United States

Site Status

Rosemark Women Care Specialists

Idaho Falls, Idaho, United States

Site Status

Women's Health Advantage

Fort Wayne, Indiana, United States

Site Status

Boston Urogynecology Associates

Cambridge, Massachusetts, United States

Site Status

Baystate Health System

Springfield, Massachusetts, United States

Site Status

Female Pelvic Medicine & Urogynecology

Grand Rapids, Michigan, United States

Site Status

Adult and Pediatric Urology & Urogynecology

Omaha, Nebraska, United States

Site Status

University of Nevada

Las Vegas, Nevada, United States

Site Status

Albany Medical Center

Albany, New York, United States

Site Status

Associated Urologists of North Carolina

Cary, North Carolina, United States

Site Status

Novant Health

Charlotte, North Carolina, United States

Site Status

Carolina Urology Partners

Gastonia, North Carolina, United States

Site Status

FirstHealth Urogynecology

Hamlet, North Carolina, United States

Site Status

Associated Urologists of North Carolina

Raleigh, North Carolina, United States

Site Status

Lyndhurst Clinical Research

Winston-Salem, North Carolina, United States

Site Status

Akron Urogynecology Associates

Akron, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Genesis Healthcare

Zanesville, Ohio, United States

Site Status

University of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

The Institute for Female Pelvic Medicine and Reconstructive Surgery

Allentown, Pennsylvania, United States

Site Status

Institute of Female Pelvic Medicine & Reconstructive Surgery

North Wales, Pennsylvania, United States

Site Status

Lexington Urology

West Columbia, South Carolina, United States

Site Status

Sanford Health

Sioux Falls, South Dakota, United States

Site Status

The Group for Women

Virginia Beach, Virginia, United States

Site Status

CHUS Hopital Fleurimont

Sherbrooke, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Erickson T, Gheiler E, Hanson CE, McCrery R, Parekh M, Parva M, Tu LM. Patient Satisfaction and QoL in SUI: Results With Single-Incision or Full-Length Slings. Urogynecology (Phila). 2025 Oct 1;31(10):942-951. doi: 10.1097/SPV.0000000000001586.

Reference Type DERIVED
PMID: 39423154 (View on PubMed)

Erickson T, Roovers JP, Gheiler E, Parekh M, Parva M, Hanson C, McCrery R, Tu LM. A Multicenter Prospective Study Evaluating Efficacy and Safety of a Single-incision Sling Procedure for Stress Urinary Incontinence. J Minim Invasive Gynecol. 2021 Jan;28(1):93-99. doi: 10.1016/j.jmig.2020.04.014. Epub 2020 Apr 19.

Reference Type DERIVED
PMID: 32320798 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SU020

Identifier Type: -

Identifier Source: org_study_id